DexCom (DXCM) PT Raised to $500 at Oppenheimer After Diabetes Device Survey
Tweet Send to a Friend
Oppenheimer analyst Steven Lichtman raised the price target on DexCom (NASDAQ: DXCM) to $500.00 (from $480.00) while maintaining a Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
